Clinical trial · Observational
the National Colorectal Cancer Cohort (NCRCC) Study: National Colorectal Cancer Research Consortium
The National Colorectal Cancer Cohort Study-Precision Medical Research in Colorectal Cancer
NCT04074538CI-TRIAL-00040359recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
NCRCC study is a national prospective cohort study including colorectal cancer screening population and stage Ⅰ-Ⅳ colorectal cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- colorectal cancer incidence
- timeFrame
- up to 15 years
- measure
- Disease-free and overall survival
- timeFrame
- up to 10 years
- measure
- Recurrence/metastasis
- timeFrame
- up to 5 years
- measure
- Adenoma or advanced adenoma incidence
- timeFrame
- up to 1 year
Secondary outcomes (2)
- measure
- Prevalence of treatment-related toxicities characterized by the Common Toxicity Criteria for Adverse Events (CTCAE)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Men and women * Mentally/physically able to consent and participate * Subjects aged ≥18 years old (Colorectal Cancer Patient Cohort, CRCPC), age 40-74 years (CRC Screening Cohort, CRCSC) * Newly-diagnosed colon and rectal cancer for stages Ⅰ-Ⅳ (CRCPC) Exclusion Criteria: * A history of colorectal cancer or bowel resection * Non-Chinese speaking
References
Publications (2)
- DERIVEDHuang F, Xiao T, Li K, Wei R, Mei S, Zhao W, Wei F, He M, Zheng Z, Liu Q. Benefit of oxaliplatin-based chemotherapy or capecitabine monotherapy in older patients with stage III and high-risk stage II colon cancer: Data from the National Colorectal Cancer Cohort study in China. Chin Med J (Engl). 2026 Jul 5;139(13):1993-2001. doi: 10.1097/CM9.0000000000003813. Epub 2025 Nov 10. PMID 41213862
- DERIVEDHuang F, Jiang S, Wei R, Xiao T, Wei F, Zheng Z, Liu Q. Association of resection margin distance with anastomotic recurrence in stage I-III colon cancer: data from the National Colorectal Cancer Cohort (NCRCC) study in China. Int J Colorectal Dis. 2024 Jul 12;39(1):105. doi: 10.1007/s00384-024-04684-x. PMID 38995409